


Read & Publish Open Access initiative



Development



Development, launched in 1953, is a leading primary research journal in the field of developmental biology. The journal publishes cutting-edge articles and reviews across the spectrum of plant and animal development.

Topic coverage ranges from stem cells and nuclear reprogramming to evolutionary developmental and systems biology, from neurobiology to regional specification, morphogenesis and organogenesis, and from epigenetics to the aetiology of disease.

In addition to primary research articles, Development publishes a range of commissioned review-based articles. These synthesise the latest advances in the field, put forward new hypotheses to provoke debate and inspire new research directions, and inform newcomers to the field.

Development was designated as one of the 100 most influential journals of the past 100 years by the SLA BioMedical & Life Sciences Division in 2009.

Readership

Development is read by scientists at all levels and from a broad field of expertise – including plant and animal biologists, geneticists, molecular biologists, cell biologists, paediatricians, neurologists, embryologists and stem cell scientists.

Abstracting and indexing services

Development is abstracted and/or indexed (amongst others) by: BIOBASE, CAB abstracts, Cambridge Scientific Abstracts, Current Contents, EMBASE, ISI Web of Science, Medline and Scopus.

Open Access commitment

The Company of Biologists has a long-standing commitment to Open Access, and our hybrid journals (including Development) were the first in the world to be awarded Transformative Journal status by Plan S. All our journals (including our fully Open Access journals – Disease Models & Mechanisms and Biology Open) are included in our Read & Publish Open Access agreements.

Key metrics

- 2022 Impact Factor: 4.6
- Five-year Impact Factor: 6.1
- Two-year citation median: 3.0
- Eigenfactor score: 0.04317
- Article Influence Score: 2.478
- Immediacy Index: 1.1
- h-index: 349
- Scopus: 8.7
- SJR indicator: 2.472
- SNIP: 1.291



Development

Available through The Company of Biologists' Read & Publish Open Access initiative



Expert team of academic editors

Editor-in-Chief

- James Briscoe (Francis Crick Institute, UK)

Deputy Editor

- Steve Wilson (University College London, UK)

Editors

- Swathi Arur (MD Anderson Cancer Center, USA)
- Benoit Bruneau (Gladstone Institutes, USA)
- Cassandra Extavour (Harvard University, USA)
- François Guillemot (Francis Crick Institute, UK)
- Anna-Katerina Hadjantonakis (Memorial Sloan Kettering Cancer Center, USA)
- Haruhiko Koseki (RIKEN Centre for Allergy and Immunology, Japan)
- Thomas Lecuit (Marseille University, France)
- Liz Robertson (University of Oxford, UK)
- Peter Rugg-Gunn (Babraham Institute, UK)
- Debra Silver (Duke University, USA)
- James Wells (Cincinnati Children's Hospital Medical Center, USA)

Associate Editors

- Paul François (McGill University, Canada)
- Matthias Lutolf (École Polytechnique Fédérale de Lausanne, Switzerland)
- Irene Miguel-Aliaga (Imperial College London and MRC-LMS, UK)
- Hanna Mikkola (University of California, Los Angeles, USA)
- Samantha Morris (Washington University in St Louis, USA)
- Ken Poss (Duke University, USA)

What are the benefits of Read & Publish agreements?

- Uncapped fee-free Open Access publishing of research articles in all our journals: Development, Journal of Cell Science, Journal of Experimental Biology, Disease Models & Mechanisms and Biology Open
- Unlimited "read" access to our three hybrid journals (Development, Journal of Cell Science and Journal of Experimental Biology) and their archives
- Transparent cost-neutral pricing
- Single annual fee covers reading and publishing
- Easy to switch from a subscription to a Read & Publish agreement
- Compliant with funder mandates including Plan S



“ The Read & Publish agreement between The Company of Biologists and the University of Cambridge made my life so easy. I could send my manuscript to Development knowing that, if accepted, publishing in my favourite journal would be straightforward, comply with my funder's requirements and be free at point of use. All that plus a free tree in The Forest of Biologists! ”

Dr Emma Rawlins, Gurdon Institute, University of Cambridge, UK

Benefits of Open Access publishing



Usage increase **>3x**




Citation advantage **1.1-1.4x**



Altmetrics boost **1.2-1.9x**

Figures based on the latest available data from Impact Vizor and Altmetric Explorer

Read & Publish: number of participating institutions



biologists.com/read-publish